AbbVie Rival Boehringer Persuades PTAB To Reexamine Humira Patent

Like Coherus BioSciences Inc., Boehringer Ingelheim GMBH convinced the US Patent & Trademark Office's Patent Trial and Appeal Board to back the company's inter partes review petition and institute a trial to consider the validity of certain claims on a patent held by AbbVie Inc. on its top-selling drug Humira (adalimumab), which also is facing competition from Amgen Inc., whose biosimilar application is under FDA review and is going before an advisory committee July 12.